SLC44A2

Across TCGA pan-cancer cohorts, SLC44A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC44A2 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC44A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC44A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where SLC44A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.534	0.899	.011	21	view →
LUAD	DFS	Quartile	II,III,IV	0.386	0.767	.004	19	view →
HNSC	DFS	Median	All	0.237	0.827	.006	18	view →
COAD	DFS	Median	IV	0.565	1.000	.028	12	view →
CCRCC	DFS	Tertile	III,IV	0.846	0.502	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC44A2–PDAC (OS)

Open the PDAC breakdown →